[vc_row][vc_column][vc_column_text]ISCT 2020 Paris will bring you highly curated scientific sessions with leading global experts within the cell and gene therapy arena.[/vc_column_text][vc_empty_space height=”10″][/vc_column][/vc_row][vc_row][vc_column width=”1/3″][vc_column_text][/vc_column_text][/vc_column][vc_column width=”1/3″][vc_column_text][/vc_column_text][/vc_column][vc_column width=”1/3″][vc_column_text][/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_empty_space height=”10″][vc_message icon_fontawesome=”fa fa-stethoscope”]97% said conference learning and networking will improve their professional performance.[/vc_message][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]

Accelerating CGT Adoption: Proof of Concept to Standard of Care

Focused on Accelerating Adoption – Proof of Concept to Standard of Care, the ISCT 2020 Annual Meeting will highlight the latest advancements in basic research, pre-clinical studies and clinical trials for a variety of therapeutic modalities including MSCs, immune effector cells, exosomes, gene-engineered cells, and iPSCs. Moreover, the breadth of therapeutic applications, regulatory aspects and manufacturing considerations for the translation of cell & gene therapies will be comprehensively addressed throughout this diverse program.[/vc_column_text][vc_empty_space][/vc_column][/vc_row][vc_row][vc_column width=”1/2″][vc_column_text]

[/vc_column_text][/vc_column][vc_column width=”1/2″][vc_column_text]

[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text el_id=”Speakers”]

Speakers

A global lineup of leading experts specializing in Translational Research, Clinical Translation, Regulatory & Quality Operations, and Commercialization. Click here to view the complete list of confirmed speakers and chairs.[/vc_column_text][vc_empty_space][/vc_column][/vc_row][vc_row][vc_column][vc_column_text el_id=”PreCon”]

Pre-Conference Day

[/vc_column_text][vc_empty_space][/vc_column][/vc_row][vc_row][vc_column width=”3/4″][vc_column_text]NEW! Investigators to Investors (i to i)

The inaugural investigators to investors (i to i) pre-conference track will bring together cell and gene therapy investors for a half-day educational event providing unparalleled access to cell and gene therapy key opinion leaders. The track will commence with a state of the industry overview and panel discussion covering topics crucial to investor due diligence, followed by meet the experts style session where attendees will have the opportunity to meet with the experts of their choosing for roundtable discussions.  

More information on featured key opinion leaders is coming soon.[/vc_column_text][vc_empty_space][/vc_column][vc_column width=”1/4″][vc_empty_space][vc_empty_space][vc_column_text][/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]NEW! Gene Therapy Pre-Conference Workshop

Brought to you by the ISCT Immuno-Gene Therapy Committee, this full-day Pre-Conference Workshop will provide the unique opportunity to gather key opinion leaders with expertise in gene therapy and tools for genetic engineering to showcase their cutting-edge research and discuss key challenges facing the gene therapy space today. Specifically, the inaugural ISCT Gene Therapy Workshop will address a variety of novel ex-vivo and in-vivo gene therapy approaches, emerging gene editing technologies and salient CMC considerations.[/vc_column_text][vc_empty_space][/vc_column][/vc_row][vc_row][vc_column width=”3/4″][vc_column_text]GRP Workshop

The ISCT Global Regulatory Perspectives (GRP) workshop represents the diverse activities and partnerships between international regulatory bodies, industry, clinicians and academia.The GRP Workshop is an annual one-day program.  Unique to this workshop is the attendance of regulators from North America, Europe, Asia, South & Central America and Australia & New Zealand.  It is a highly interactive program including various hypothetical case studies throughout.[/vc_column_text][/vc_column][vc_column width=”1/4″][vc_empty_space][vc_column_text][/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_empty_space][vc_column_text]MSC Track

Organized by the ISCT MSC Scientific Committee, the Society’s scientific thought leadership on MSCs, this Pre-Conference Day Track provides the unique opportunity to bring together preeminent leaders from around the world to present their cutting-edge research and discuss key challenges related to discovery, development and clinical deployment of mesenchymal stromal cells.[/vc_column_text][vc_empty_space][vc_column_text]ISCT-Cord Blood Connect
in partnership with WMDA

Formerly the ISCT-CBA Cord Blood Series, the newly branded ISCT-Cord Blood Connect is brought to you by ISCT and the Cord Blood Association (CBA), now in partnership with the World Marrow Donor Association (WMDA). For the sixth consecutive year, join the world’s leading cord blood experts at the ISCT Annual Meeting to learn about the latest advancements in cord blood biology and transplantation, and its application in the translation of novel cell therapies.[/vc_column_text][vc_empty_space][vc_column_text]Cell Processing Track

Join the journey from ‘Needle to Needle’ as the 2020 Cell Processing Track features a carefully curated program offering a unique look into the production of cell-based products, with a focus on novel processing techniques including gene editing, cell activation and expansion  and characterization by flow cytometry. This practical workshop will provide delegates an opportunity to dig into the details of what it takes to bring a product from bench to bedside.[/vc_column_text][vc_empty_space][/vc_column][/vc_row][vc_row][vc_column][vc_column_text el_id=”Plenaries”]

Plenary Sessions

With the goal of Accelerating CGT Adoption – Proof of Concept to Standard of Care, the ISCT 2020 Scientific Plenary Sessions will each feature 3 diverse presentations addressing the latest advancements in translational research, pre-clinical studies, and clinical trials for a variety of therapeutic applications. Plenary Sessions will each be accompanied by two Plenary Satellite Sessions, allowing for a comprehensive overview of latest advancements and emerging strategies in each therapeutic area of focus.
 

Presidential Plenary – Mastering Pluripotent Cells with Therapeutic Intent

Plenary Satellite Sessions:

  • Cardiovascular
  • iPSC Derived Organoids

[/vc_column_text][vc_empty_space][vc_column_text]Plenary 2: Mesenchymal Stromal Cells- Full Circle from Basic Research Insights to Clinical Trial Updates

This session will bring together speakers who will provide a full spectrum overview of latest developments in the field of mesenchymal stromal cell research. This includes insights into newly hypothesized mechanisms of action and single cell characterization of mesenchymal stromal cells, clinical translation challenges using pooled bone marrow-derived mesenchymal stromal cells for treatment of refractory Graft-vs. Host Disease, and updates from a pioneering European trial on the use of mesenchymal stromal cells to treat refractory Sclerodoma.

Plenary Satellite Sessions:

  • MSC Mechanism of Action
  • Musculoskeletal Therapies

[/vc_column_text][vc_empty_space][vc_column_text]Plenary 3: Advances and Emerging Technologies in Immune-Mediated Cancer Treatments

CAR-T Cells represent the first example of a cellular therapy that has moved from immunological concepts developed in research laboratories to worldwide and large-scale industry-manufacturing of potent therapeutic agents. The bumpy road* for these developments exemplify the many scientific challenges that await developers of this class of therapeutics. While scientific developments continue to occur at a high pace for CAR-T and CAR NK therapies, the race to solve the logistical, medical, financial and societal issues is engaged, with the goal to bring this class of therapeutics to all patients in need of them. CAR-T and CAR NK Cells will likely pave the way for other forms of immune cellular therapies, but also for regenerative medicines. 

Plenary Satellite Sessions:

  • CART for Solid Tumors
  • Immunotherapy

[/vc_column_text][vc_empty_space][vc_column_text]Plenary 4: Is Big Pharma ready for industrial scale Cell and Gene Therapy?

Recent successes in the market authorization of cell and gene therapy products has generated tremendous excitement. However, to be successful, the industry now needs to move into a phase of industrialization, where like the car industry it needs the “eureka” moment of standardization that allows the efficient flow from product to patient. To realize this, we need to overcome the barriers between all the silos in the system (e.g. hospital, manufacture, testing, etc.) so that patients are efficiently treated.

Plenary Satellite Sessions:

  • Industrializing Clinical Delivery
  • Industrializing the Last 100m

[/vc_column_text][vc_empty_space][vc_column_text]Plenary 5: Gene Engineering: The Past, Present and the Future

Gene-engineering is currently ‘in-vogue’ as a potential treatment for multiple monogenetic and rare diseases. This session will highlight the progress in the field of gene-insertion, vector biology and gene-editing for both the ex-vivo and in-vivo approaches of gene manipulation. The current challenges and safety issues will be discussed, with the spotlight on ongoing clinical trials as examples of potential curative therapies.

Plenary Satellite Sessions:

  • Stem Cell Based Clinical Trials
  • Gene Therapy Clinical Trials

[/vc_column_text][vc_empty_space][vc_column_text]Plenary 6: Basics and translational potential of extracellular vesicles including exosomes

Most cells release Extracellular Vesicles (EVs) into their environment. In particular, small EVs of 50-200 nm that include exosomes, have been shown to mediate intercellular communication in many physiological and pathophysiological processes. Small EVs from some cell sources, e.g. mesenchymal stromal cells (MSCs), can alleviate pathological processes and are considered as novel therapeutic agents. Within the session basic aspects of EV biology and their therapeutic potential will be discussed.

Plenary Satellite Sessions:

  • EV Technical Session
  • MSC-EVs

[/vc_column_text][vc_empty_space][/vc_column][/vc_row][vc_row][vc_column][vc_column_text el_id=”Concurrent”]

Concurrent Tracks

Quality & Operations (Q&O)

Quality implications are crucial for the success of cell and gene therapy development. Targeted at technical and quality personnel, the 2020 Quality and Operations Track will share key learnings in manufacturing process validation, regulatory CMC considerations, starting and raw material selection, analytical tools and methods and GMP manufacturing challenges.  Experts from around the world will discuss regional nuances and global implications for harmonization of the cell and gene therapy industry across academia, industry and regulatory agencies.[/vc_column_text][vc_empty_space][vc_column_text]Strategies for Commercialization (SFC)

Hear from industry leaders developing solutions to the most prominent challenges facing the cell and gene therapy industry. The 2020 Strategies for Commercialization track theme, moving from commercialization to industrialization, will share critical strategies required to tackle scale up and optimization challenges as more cell and gene therapy products reach the market. Learn how to optimize your manufacturing process, overcome logistics challenges, leverage fast track regulations in your commercialization plan, evaluate and improve your business model, raise capital, and ultimately contribute to the goal of delivering more cell and gene therapies to patients.[/vc_column_text][vc_empty_space][vc_column_text]Advanced Practice Professionals (APP)

More information coming soon.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]

And Many More…

Maximize your experience and engage in all aspects of the multifaceted program on offer. Curated by your peers to address the depth and breadth of cell and gene therapy translation, the ISCT 2020 scientific program will feature a variety of concurrent sessions calling attention to key takeaways and emerging concepts in the cell & gene therapy space in 2020.[/vc_column_text][/vc_column][/vc_row]